Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Change in Accured Expenses (2019 - 2026)

Alx Oncology Holdings' Change in Accured Expenses history spans 5 years, with the latest figure at $4.7 million for Q4 2023.

  • On a quarterly basis, Change in Accured Expenses rose 669.59% to $4.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $11.2 million, a 59.73% increase, with the full-year FY2025 number at $2.0 million, up 115.86% from a year prior.
  • Change in Accured Expenses hit $4.7 million in Q4 2023 for Alx Oncology Holdings, down from $8.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ALXO hit a ceiling of $8.3 million in Q3 2023 and a floor of -$5.6 million in Q1 2023.
  • Historically, Change in Accured Expenses has averaged $1.5 million across 5 years, with a median of $934000.0 in 2020.
  • The widest YoY moves for Change in Accured Expenses: up 669.59% in 2023, down 325.69% in 2023.
  • Tracing ALXO's Change in Accured Expenses over 5 years: stood at $425000.0 in 2019, then skyrocketed by 603.06% to $3.0 million in 2020, then plummeted by 67.44% to $973000.0 in 2021, then crashed by 36.79% to $615000.0 in 2022, then soared by 669.59% to $4.7 million in 2023.
  • Business Quant data shows Change in Accured Expenses for ALXO at $4.7 million in Q4 2023, $8.3 million in Q3 2023, and $3.7 million in Q2 2023.